$CRVO

CervoMed Inc. (NASDAQ: CRVO) reported at AAIC 2026 new Phase 2b analyses for neflamapimod in dementia with Lewy bodies. The company said results support selecting 50 mg TID for a planned Phase 3, citing effects on CDR-SB, plasma pTau181 exposure, and MRI basal forebrain atrophy/connectivity. It also reported Phase 2 data for 80 mg BID meeting safety and PK objectives.

CervoMed (NASDAQ: CRVO) said it completed enrollment in a Phase 2a trial of oral p38a inhibitor neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA). The study enrolled 25 patients and includes 24 weeks of dosing plus a 12-week randomized placebo-controlled extension. Interim biomarker data are slated for CTAD in Nov 2026, with first biomarker and clinical data expected Q4 2026 and Q1 2027.

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 ex_978640.htm EXHIBIT 4.1 ex_978640.htm Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FR

BOGER JOSHUA S purchased 955,414 indirectly-held shares of CervoMed Inc. (CRVO) at $3.14 ($3.00M total) on 2026-06-11.

CervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, extending its cash runway into Q2 2027, according to the company. Funds will support a strategic partnership to advance neflamapimod into Phase 3 for dementia with Lewy bodies. Over six months, it expects Phase 2a 24-week biomarker/clinical data and to start EXPERTS-ALS Phase 2a.

CervoMed (NASDAQ: CRVO) said it entered a definitive agreement for a private placement expected to raise about $10.5 million in upfront gross proceeds, with net proceeds extending its cash runway into Q2 2027. The company plans to prioritize securing a strategic partner to advance neflamapimod to Phase 3 for dementia with Lewy bodies. It also cited upcoming Phase 2a milestones in nfvPPA and ALS.

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex_974988.htm EXHIBIT 10.1 ex_974988.htm Exhibit 10.1 Execution Version CERVOMED INC. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (the “ Agreement ”) is made as of June 9, 2026 (the “ Effective Date ”), by and between CervoMed Inc. , a Delaware corp

CervoMed Inc. (CRVO) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. crvo20260609_8k.htm false 0001053691 0001053691 2026-06-08 2026-06-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 June 8, 2026 Date of Report (Date of earlie

MarketBeat.com compares medical firms CervoMed (NASDAQ:CRVO) and Pathfinder Cell Therapy (OTCMKTS:PFND). It cites institutional ownership of 25.2% for CervoMed versus 15.1% insiders for Pathfinder, and notes CervoMed has a consensus price target of $22.60. The article says CervoMed outperforms Pathfinder on 6 of 9 factors, including analyst ratings and possible upside.

This article provides details regarding the number of shareholders for CervoMed Inc., traded under the NASDAQ:CRVO symbol. The information is presented on a TradingView page, which also lists various financial and market data resources available for the company. The content primarily focuses on the display of shareholder data, emphasizing that the market is closed without any trades.